Business Wire

CITY-OF-TAMPERE

Share
City of Tampere: an International Ideas Competition in a Magnificent Finnish Lakeside City

An international ideas competition started off on 15 May 2019 in Viinikanlahti, a highly exciting area close to Tampere city centre. Competitors get to design a housing area of over 3,000 residents on the shores of Lake Pyhäjärvi, as well as a leisure time environment for the locals and tourists. With a population of roughly 370,000, the sustainably growing Tampere is the largest inland city in the Nordic Countries and, together with the neighbouring municipalities, forms the second-largest urban area in Finland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515005494/en/

The aim of the ideas competition, which is open to all, is to create a new and ecologically sustainable city district that boasts high-quality architecture and meets the needs of the 21st century. The competition task is exceptionally interesting: the unique Viinikanlahti area has the most beautiful lake views in the centre of Tampere, but also involves environmental challenges. The size of the competition area (land and water) is roughly 0.4 hectares. The wastewater treatment plant currently operating in the area will be moved elsewhere. After the competition, both a master plan and a local detailed plan will be prepared for the area. The environment will be cleaned and the new city district constructed in phases between 2024-2035.

The international ideas competition is organised mainly digitally, and is expected to attract plenty of participants from Finland and abroad. A total of 165,000–345,000 euros will be awarded in prizes in the two-phased competition, the winner of which will be selected in April 2020. The competition is organised by the City of Tampere in cooperation with the Finnish Association of Architects (SAFA) and the Association of Finnish Landscape Architects (MARK).

The economy of the City of Tampere focuses on services and high-technology. Innovative, digital, and sustainable smart city solutions are being created in the region together with companies, research institutions, municipalities, and residents. The population of Tampere is increasing by over 3,000 residents a year. New construction is constantly being implemented in the area, and new ecological and low-emission solutions are needed to enable the carbon-neutral and sustainable growth of the city in accordance with its strategy.

Competition website:

www.tampere.fi/viinikanlahti

Further information:

https://businesstampere.com/

https://visittampere.fi/en/

YouTube: @tampereenkaupunki

Contact:

Executive Director, Growth, Innovation and Competitiveness Services Teppo Rantanen +358 400235442 teppo.t.rantanen@tampere.fi Project Director Tero Tenhunen +358 505402860 tero.tenhunen@tampere.fi Project Development Manager Minna Seppänen +358 401509857 minna.seppanen@tampere.fi

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release

SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye